BAX Baxter International

Q3 2025 10-Q

Filed: Nov 4, 2025Period ending Sep 30, 2025

Health Care

Surgical & Medical Instruments & ApparatusSEC EDGAR

Baxter International (BAX) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $2.835B Q3 2025 vs $2.699B Q3 2024; Medical Products & Therapies down 1%, Healthcare Systems & Technologies up 3%, Pharmaceuticals up 7% YoY
• Operating margin by segment Q3 2025: Medical Products & Therapies 20.5% vs 20.0% YoY, Healthcare Systems & Technologies 13.5% vs 18.1%, Pharmaceuticals 8.9% vs 9.9%

+3 more insights

Risk Factors

• No material changes in risk factors from 2024 Annual Report
• Continued exposure to regulatory approval delays impacting product launches

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$2.8B

▲ +491.9% YoY▲ +0.9% QoQ

Net Income

-$46M

▼ -132.9% YoY▼ -150.5% QoQ

Net Margin

-1.6%

▼ -3085bp YoY▼ -486bp QoQ

Source: XBRL data from Baxter International Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Baxter International

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.